BCDA Q3'26 Earnings: EPS estimate is (0.13) USD
BioCardia (BCDA) will report Q3'26 earnings on November 12. Analysts expect $0 revenue and a loss of $0.13 per share. Results will be released after market close.
How this was made

The 30-second read
Why it matters
The negative EPS estimate may set expectations for a price decline unless the actual results exceed the forecast.
Market read
The preview influences short‑term trading decisions for BCDA and may affect sentiment in the broader biotech space.
What to watch
Potential upcoming clinical data or partnership announcements not mentioned could offset the loss forecast.
Background
BioCardia is a small‑cap biotech that reports quarterly results on a scheduled basis.
Ticker impact
Article provides the Q3'26 earnings estimate (EPS (0.13) USD) ahead of the November 12 release.
potential pressure if actual earnings miss the -0.13 USD estimate
The negative EPS estimate signals a loss, which could lead to sell‑off unless the actual results beat expectations.
Market effects
Biotech sector may see slight bearish sentiment as a peer reports a loss forecast.
US small‑cap biotech investors may adjust positions ahead of the release.
Limited to investors tracking BioCardia and comparable biotech earnings.
Counterpoint
If the company surprises to the upside, the stock could rally sharply despite the negative estimate.
Key entities
- companyBioCardia, Inc.
US‑listed biotech (NASDAQ: BCDA) reporting Q3'26 earnings.

